National Bank of Canada’s Grace Therapeutics GRCE Stock Holding History

National Bank of Canada’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.08K	Sell	2,680 -36	-1%	-$100	﹤0.01%	2524
2026 Q1	$12.6K	Hold	2,716	–	–	﹤0.01%	2279
2025 Q4	$9.37K	Hold	2,716	–	–	﹤0.01%	2327
2025 Q3	$8.04K	Hold	2,716	–	–	﹤0.01%	2367
2025 Q2	$8.07K	Sell	2,716 -2	-0.1%	-$5	﹤0.01%	2401
2025 Q1	$6.12K	Sell	2,718 -1	-0%	-$3	﹤0.01%	2346
2024 Q4	$10.2K	Hold	2,719	–	–	﹤0.01%	2323
2024 Q3	$8.12K	Sell	2,719 -182	-6%	-$487	﹤0.01%	2128
2024 Q2	$8.29K	Hold	2,901	–	–	﹤0.01%	2165
2024 Q1	$7.97K	Hold	2,901	–	–	﹤0.01%	2217
2023 Q4	$7.97K	Hold	2,901	–	–	﹤0.01%	2216
2023 Q3	$8.13K	Sell	2,901 -169	-6%	-$400	﹤0.01%	2242
2023 Q2	$9.66K	Hold	3,070	–	–	﹤0.01%	2194
2023 Q1	$8.39K	Hold	3,070	–	–	﹤0.01%	2186
2022 Q4	$8.86K	Buy	3,070 +2,521	+459%	+$7.43K	﹤0.01%	2214
2022 Q3	$2K	Sell	549 -2,521	-82%	-$12.4K	﹤0.01%	2548
2022 Q2	$16K	Hold	3,070	–	–	﹤0.01%	2144
2022 Q1	$22K	Buy	3,070 +161	+6%	+$1.15K	﹤0.01%	2156
2021 Q4	$22K	Buy	+2,909	New	+$26.2K	﹤0.01%	2149

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

National Bank of Canada's GRCE Position: Q2 2026 in Review

National Bank of Canada reduced its Grace Therapeutics (GRCE) stake by 1.3% in Q2 2026, selling an estimated $100 and leaving 2,680 shares worth $6.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2524.

National Bank of Canada first reported a position in GRCE in Q4 2021 and has held it in 19 quarters since. The position peaked at $22K in Q1 2022. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

National Bank of Canada held 2,680 shares of Grace Therapeutics worth $6.08K as of Q2 2026.
National Bank of Canada sold 36 Grace Therapeutics shares in Q2 2026, an estimated $100.
Grace Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2524 holding.
National Bank of Canada first reported a position in Grace Therapeutics in Q4 2021 and has held it in 19 quarters since.
National Bank of Canada's Grace Therapeutics position peaked at $22K in Q1 2022.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.